HOLLISTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Chief Financial Officer, will
HOLLISTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended September 30, 2026, before the market opens on November 10, 2026,
HOLLISTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced the creation of its Scientific Advisory Board (SAB) to guide the Company’s ongoing research, development, and
Second Quarter 2026 Revenue Growth of 11% Year Over Year to $22.7 Million Raises Full Year 2026 Revenue Guidance to 3%-5% Year Over Year Growth HOLLISTON, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience,
HOLLISTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended June 30, 2026, before the market opens on August 11, 2026, and will
First Quarter 2026 Revenues of $20.8M and Gross Margin of 59%Consolidation of Manufacturing Operations Progressing on ScheduleReaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12, 2026 (GLOBE
HOLLISTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced Chief Executive Officer, John Duke and Chief Financial Officer, Mark Frost's participation in the following
HOLLISTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended March 31, 2026, before the market opens on May 12, 2026, and will
Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7%Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7%Interim CFO Mark Frost Appointed CFO on Permanent BasisIntroduces Full Year 2026 Guidance which
Harvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the
HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief Financial Officer, will
HOLLISTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended December 31, 2025, before the market opens on March 12, 2026, and
Reports preliminary fourth quarter revenue in line with guidance, gross margin at high end of guidance, and strong year over year adjusted EBITDA performance Expects year over year revenue growth and mid-to
Streamlining production footprint and improving manufacturing efficiency through phased closure of Holliston, MA plant Initiative expected to deliver approximately $3 million in cost savings in 2027 and $4 million in
Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial FlexibilityBroadOak Partner Bill Snider to Join Board of Directors and Company to Form Advisory Board on Growth and
